Drug-eluting stents

Antiplatelet

Results of Zotarolimus-Eluting Stents vs Biolimus-Eluting Polymer-Free Stents After 2 Years. Are They Safe in Patients at High Risk for Bleeding?

The proportion of patients treated with coronary angioplasty who are at a high risk for bleeding is...

solaci - 22 June, 2022

Coronary disease

Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results

Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent...

solaci - 13 June, 2022

Coronary disease

Should We Start Thinking Again About Bioresorbable Stents?

Coronary revascularization with drug-eluting stents (DES) is very frequent, especially in acute coronary syndromes, but these metallic...

solaci - 9 June, 2022

Coronary disease

Revascularization Using DES in Infrapopliteal Disease: Meta-Analysis and Change of Paradigm?

Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke,...

solaci - 1 June, 2022

Acute coronary syndromes

Coronary Angioplasty Evolution According to Syntax II: 5-Year Followup

It has been long since the SYNTAX (NEJM 2009) came out comparing percutaneous coronary intervention (PCI) against...

solaci - 5 May, 2022

Coronary disease

IVUS-Guided Coronary Angioplasty: Promising Results at 3-Year Follow-Up

Intravascular ultrasound (IVUS) to guide drug-eluting stent (DES) implantation has been evaluated in several studies. Two randomized...

solaci - 2 May, 2022

Coronary disease